Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : opens application window for Grants4Ag

share with twitter share with LinkedIn share with facebook
09/21/2020 | 10:35am EDT
Monday - September 21, 2020
Initiative offers financial support for novel approaches and enabling technologies in crop research
Bayer opens application window for Grants4Ag
downloadBayer supports the search for new approaches that lead to innovative solutions in plant research.

Monheim, September 21, 2020 - Bayer announced today that it has opened the application window for its Grants4Ag initiative. First introduced in 2015, the initiative has evolved in 2020 to offer researchers financial and scientific support to develop ideas for novel solutions across all research and development areas in the Division of Crop Science. Deadline for submissions is October 31, 2020.

'Our previous Grants4 programs succeeded in attracting top proposals in targeted niches - particularly biotech traits and biologicals,' said Phil Taylor, Open Innovation Business Partner for the Crop Science division. 'The new Grants4Ag model expands the reach to a greater number of potential applicants, and therefore more diverse innovations.'

As with previous Grants4 programs, there are no formal reporting requirements and applicants retain ownership of any intellectual property developed. Taylor says the company views these grants as an initial investment with the potential to become larger-scale, longer-term collaborations with Bayer.

In addition to the grants (typically ranging from 5,000 to 15,000 euros), each recipient will be partnered up with a Bayer scientist who will provide guidance and feedback on the project. Previous grant recipients say the latter sets the Grants4 program apart from traditional funding programs.

'The Bayer Grants4 program is easy to apply for and allows us to test technologies with feasibility experiments whose results can bridge current and future projects,' said Hank W. Bass, Professor of Biological Science at Florida State University, who was awarded a grant in 2019 to study corn plants' response to flooding.

In total, last year's grants program received submissions from 17 countries around the world. A total of 21 grants were awarded.

For the 2020 Grants4Ag submission period, Bayer is partnering with Halo, a marketplace that helps companies connect with scientists through an intuitive, streamlined interface.

'We created Halo to help companies discover and collaborate with scientists to solve today's challenges and stay a step ahead of tomorrow's,' said Kevin Leland, CEO and Founder of Halo. 'Bayer has long been a champion of open innovation and we're thrilled to be powering this latest search so even more scientists from universities and startups can benefit from its resources and industry knowledge.'

Full details on the programs' sought-after solutions, application process and submission rules are available at halo.science/company/bayer-crop-science.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.


Bayer AG published this content on 21 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 September 2020 13:34:05 UTC

share with twitter share with LinkedIn share with facebook
All news about BAYER AG
09:47aBAYER : Rivaroxaban application submitted to U.S. FDA for new indication in pati..
09:46aBAYER : acquires Asklepios BioPharmaceutical to broaden innovation base in cell ..
09:32aBAYER : Appoints New Head of R&D at Pharmaceuticals
09:10aBAYER : appoints Dr. Christian Rommel as new Head of Pharmaceuticals Research an..
05:51aCapgemini shares advance on better-than-expected Q3 growth
10/26Health Care Shares Decline as Covid-19 Continues to Dominate Headlines -- Hea..
10/26NEWS HIGHLIGHTS : Top Company News of the Day
10/26NEWS HIGHLIGHTS : Top Company News of the Day
10/26NEWS HIGHLIGHTS : Top Company News of the Day
10/26WALL STREET STOCK EXCHANGE : US companies under China sanctions, Many acquisitio..
More news
Sales 2020 42 947 M 50 791 M 50 791 M
Net income 2020 -4 852 M -5 738 M -5 738 M
Net Debt 2020 32 409 M 38 329 M 38 329 M
P/E ratio 2020 -7,02x
Yield 2020 5,68%
Capitalization 41 807 M 49 406 M 49 443 M
EV / Sales 2020 1,73x
EV / Sales 2021 1,69x
Nbr of Employees 101 168
Free-Float 100,0%
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 67,53 €
Last Close Price 42,56 €
Spread / Highest target 116%
Spread / Average Target 58,7%
Spread / Lowest Target 8,10%
EPS Revisions
Werner Baumann Chairman-Management Board
Norbert Winkeljohann Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-41.55%49 406
JOHNSON & JOHNSON-1.30%379 007
ROCHE HOLDING AG-4.55%282 543
PFIZER INC.-3.22%210 717
MERCK & CO., INC.-13.32%199 405
NOVARTIS AG-16.94%185 381